Orphelia Pharma

17 September 2019

Dr Bonnefoy to inaugurate first CyTOF Hyperion in France

Nathalie Bonnefoy, cofounder of OREGA Biotech and deputy director of Institut de Recherche en Cancérologie de Montpellier (IRCM), will inaugurate the first CyTOF Hyperion in France on September 18, 2019 at IRCM. Equipped with a very innovative technology, the CyTOF Hyperion will make it possible to explore tumor heterogeneity from a biopsy by very finely mapping tumor cells in their microenvironment, including the interactions with and between the immune cells. The CyTOF is a powerful tool for immuno-oncology studies. It reveals the structure of disease tissue at the single cell level and enables the characterization with up to 50 markers, from a single slide, of the spatial distribution and the cellular network with immune cells.
27 July 2019

Anti-CD39 mAb publication in Cell Reports

The publication of preclinical data of the CD39-blocking monoclonal antibody IPH5201 appears in the May 21, 2019 issue of the journal Cell Reports.  Read the full manuscript titled “Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies”
Meet us at the 2018 Bio Europe meeting in Copenhagen
This website uses cookies to improve your experience. By using this website you agree to our Data Protection Policy.
Read more